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Abstract
Background—Recent genetic and pharmacological evidence indicates that low neuropeptide Y
(NPY) levels in brain regions involved with neurobiological responses to ethanol promote increased
ethanol consumption. Because of their opposing actions, it has been suggested that NPY and
corticotropin releasing factor (CRF) exert a reciprocal regulation on drug self-administration. It has
been widely reported that inbred C57BL/6 mice consume significantly higher amounts of ethanol
than do DBA/2 mice. Therefore, we used immunohistochemical techniques to determine if basal
NPY and/or CRF levels differed in predicted directions between C57BL/6J and DBA/2J mice.
Methods—Ethanol-naive C57BL/6J and DBA/2J mice were deeply anesthetized with sodium
pentobarbital (100 mg/kg) and perfused transcardially with 0.1 mM of phosphate-buffered saline
followed by 4% paraformaldehyde in buffered saline. Brains were collected and postfixed for 4 hr
at 4°C and then were cut into 35-μm sections. Tissues containing the nucleus accumbens (NAc),
hypothalamus, and amygdala were processed for NPY or CRF immunoreactivity using
immunofluorescent or DAB techniques. Immunoreactivity was quantified from digital images using
Image J software.
Results—The C57BL/6J mice showed reduced NPY expression in the NAc shell, the basolateral
amygdala, and the central nucleus of the amygdala when compared with DBA/2J mice. However,
these strains did not differ in CRF expression in any of the brain regions analyzed.
Conclusions—These data suggest that low NPY levels in the amygdala and/or the shell of the
NAc, which are not compensated for by similar changes in CRF levels, may contribute to the high
ethanol consumption characteristic of C57BL/6J mice.
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NEUROPEPTIDE Y (NPY) is a 36 amino acid neuro-modulator belonging to the PP-fold
family of peptides (Berglund et al., 2003; Colmer and Wahlestedt, 1993; Dumont et al.,
1992). NPY immunoreactivity (IR) has been noted in brain regions such as the amygdala,
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cerebral cortex, caudate putamen, hippocampus, hypothalamus, and nucleus of the solitary
tract (Gray and Morley, 1986) and has been shown to be involved in the regulation of a wide-
ranging group of biological functions. It has been implicated in the control of food intake
(Clark et al., 1984; Levine and Morley, 1984), cardiovascular homeostasis (Pedrazzini et al.,
1998), integration of emotional behavior (Heilig et al., 1993; Heilig and Widerlov, 1995),
neuronal development (Hansel et al., 2001a,b), seizure activity (Woldbye et al., 1996, 1997),
pain modulation (Shi et al., 1999, 2001), thermogenesis (Lopez-Valpuesta et al., 1996),
circadian rhythms (Biello et al., 1997; Golombek et al., 1996; Gribkoff et al., 1998; Harrington
and Schak, 2000), and reproduction (Kalra et al., 1998; Kasuya et al., 1998).
In recent years, evidence has emerged showing that NPY is also involved with neurobiological
responses to ethanol (Pandey et al., 2003a; Thiele and Badia-Elder, 2003; Thiele et al., 2003,
2004b). Specifically, administration of ethanol and ethanol withdrawal alter central NPY
expression in rodents (Bison and Crews, 2003; Clark et al., 1998; Ehlers et al., 1998; Kinoshita
et al., 2000; Roy and Pandey, 2002; Thiele et al., 2000a). Further, NPY has been implicated
in the modulation of ethanol consumption in rats selectively bred for ethanol preference. A
genetic linkage analysis conducted in F2 intercross progenies of selectively bred alcohol-
preferring (P) and -nonpreferring (NP) rat lines identified a chromosomal region that includes
the gene for the NPY precursor (Bice et al., 1998; Carr et al., 1998; Foroud et al., 2000). P rats
and the high alcohol drinking (HAD) rats have low levels of NPY in the amygdala when
compared with controls (Ehlers et al., 1998; Hwang et al., 1999), and ventricular administration
of NPY reduces ethanol drinking in P and HAD rats but not in NP rats, low alcohol drinking
(LAD) rats, or outbred Wistar rats (Badia-Elder et al., 2003; Badia-Elder et al., 2001; Gilpin
et al., 2003; Katner et al., 2002a,b; Slawecki et al., 2000). Interestingly, in genetically modified
mice, voluntary ethanol consumption and resistance to the intoxicating effects of ethanol are
inversely related to NPY levels (Thiele et al., 1998, 2000b, 2002, 2004a).
Corticotropin releasing factor (CRF) is a 41 amino acid polypeptide that is expressed in many
of the same brain regions as NPY, including the hypothalamus and amygdala (Swanson et al.,
1983). Interestingly, NPY and CRF often produce opposing neurobiological actions. Thus,
after ethanol withdrawal, there are low levels of NPY (Pandey et al., 2003b; Roy and Pandey,
2002) and increased levels of CRF (Merlo Pich et al., 1995) in the amygdala. Furthermore,
central infusion of NPY (Pandey et al., 2003b) or CRF receptor antagonists (Breese et al.,
2004; Knapp et al., 2004; Overstreet et al., 2004; Rassnick et al., 1993) reverses the anxiogenic
effect of ethanol withdrawal. Of critical interest, while NPY decreases ethanol consumption
in high ethanol drinking models (Badia-Elder et al., 2003; Badia-Elder et al., 2001; Gilpin et
al., 2003), central infusion of the CRF receptor antagonist D-Phe-CRF(1,2-14) eliminates
excessive ethanol drinking by rats made dependent with chronic exposure to ethanol vapor
(Valdez et al., 2002). Because of their opposing actions, it has been suggested that CRF and
NPY exert a reciprocal regulation of drug self-administration through allostatic interactions
within the extended amygdala (Koob, 2003; Koob and Le Moal, 2001).
The goal of the present study was twofold. First, we determined if ethanol consumption was
inversely related to NPY levels in two inbred strains of mice that differ dramatically in their
voluntary consumption of ethanol (Belknap et al., 1993; Le et al., 1994; Meliska et al., 1995;
Mittleman et al., 2003; Risinger et al., 1998). C57BL/6J mice voluntary consume 10–12 g/kg/
day of ethanol when offered a 10% (v/v) solution, while DBA/2J mice consume approximately
1.0 g/kg/day (Belknap et al., 1993). Second, because of the proposed relationship between NPY
and CRF, we determined if C57BL/6J and DBA/2J mice also differed in central CRF levels.
Immunohistochemistry procedures were used to determine NPY and CRF levels in critical
brain regions within the hypothalamus and the extended amygdala. On the basis of observations
utilizing genetically altered mice and selectively bred rats, we predicted that C57BL/6J mice
would have low NPY levels in specific brain regions when compared with DBA/2J mice.
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Furthermore, because excessive ethanol drinking may be modulated by enhanced CRF receptor
signaling (Valdez et al., 2002), we predicted that the C57BL/6J mice would also differ from
the DBA/2J mice in brain CRF levels.
MATERIALS AND METHODS
Subjects
Consistent with prior experiments that assessed NPY levels in P/NP and HAD/LAD rats (Ehlers
et al., 1998; Hwang et al., 1999), male mice were used in the present study. Subjects were 13
DBA/2J mice and 12 C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) obtained at 7
weeks of age and weighing between 20 and 26 g at the beginning of the experiment. Mice were
individually housed for 2 weeks with ad libitum access to standard rodent chow (Teklad,
Madison, WI) and water and maintained at 22°C on a 12 hr:12 hr light/dark cycle. All
experiments were conducted in compliance with the National Institutes of Health guidelines,
and the University of North Carolina Animal Care and Use Committee approved the protocols.
Tissue Preparation
Animals were weighed approximately 90 min before the beginning of the perfusions. Mice
were injected intraperitoneally with pentobarbital (100 mg/kg) in their home cages in pairs,
one C57BL/6J and one DBA/2J, and were then transported and perfused transcardially with
0.1 mM of phosphate-buffered saline (PBS; pH 7.4) followed by 4% paraformaldehyde in
buffered saline. Because of rapid onset of hypnosis, perfusions were begun within 5 min of
injection. Because mice were injected in their home cages and because perfusions were
conducted within 5 min of drug injection, stress- or drug-induced alteration of either CRF or
NPY appears unlikely. In fact, heteronuclear transcripts of CRF do not appear to be increased
until 20–40 min after ethanol injection (Rivier and Lee, 1996). The brains were collected and
postfixed in paraformaldehyde for 4 hr at 4°C, at which point they were transferred to PBS.
The brains were then packaged and sent to NeuroScience Associates (Knoxville, TN) for multi-
brain processing in which the 25 brains were embedded together in a matrix and sliced as a
unit into 35-μm sections. Brains were returned in a cryopreservation solution (1:1 0.2 M
phosphate buffer: ethylene glycol with 1% w/v polyvinylpyrrolidone 40) and stored at 4°C
until immunohistochemical analyses.
NPY Immunohistochemical Analysis and Quantification
Tissue slices containing the brain regions of interest were washed in PBS and then blocked in
a solution containing 10% goat serum and 0.1% Triton X-100 for 1 hr. The slices were then
incubated with rabbit anti-NPY antibody (1:1000; Peninsula Laboratories, San Carlos, CA)
and 3% goat serum for approximately 72 hr at 4°C. After multiple washes with PBS, slices
were incubated with Alexa Flour 594 antirabbit secondary antibody (1:1000; Molecular Probes,
Eugene, OR) and 3% goat serum for 1 hr at room temperature in the dark. As a control to assess
potential nonspecific staining, some sections were run through the assay without primary or
without secondary antibodies, and no staining occurred. Slices were then mounted onto 75 ×
50-mm Corning microslides (Corning, Corning, NY) using fluorescence mounting media. The
tissue was visualized using an Olympus M081 microscope with a 10× objective (Olympus,
Melville, NY). Photographs were obtained with a 35-mm Olympus OM-4Ti camera using
Fujifilm Provia Professional film (Fujifilm, Edison, NJ). Photographs were converted to 35-
mm slides and then to digital images using a Polaroid Sprint Scan 4000 with PolarInsight
software (Polaroid, Charlotte, NC). Immunofluorescence was quantified using Image J
software (Image J, National Institutes of Health, Bethesda, MD) by calculating the percent of
the total area examined that showed immunofluorescence reactivity relative to a subthreshold
background. For analyses, great care was taken to match sections through the same region of
brain and at the same level using anatomical landmarks. Anatomically matched pictures of the
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left and right sides of the brain were used to produce an average IR score for each brain region
in each animal.
CRF Immunohistochemical Analysis and Quantification
CRF IR utilized the DAB method of staining rather than immunofluorescence because a
constant procedure has been established in our laboratory. However, a pilot comparison of
CRF IR using DAB and immunofluorescent procedures yielded similar levels of expression
(data not shown). Tissue slices were washed in PBS and then blocked in a solution containing
0.1% Triton X-100 and 10% goat serum for 1 hr. The slices were then incubated with rabbit
anti-CRF antibody (1:1000; Peninsula Laboratories) and 3% goat serum for approximately 72
hr at 4°C. After multiple PBS washes, slices were incubated with biotinylated secondary
antibody from the VectaStain rabbit ABC kit (Vector Laboratories, Burlingame, CA) and 3%
goat serum for 1 hr at room temperature. After several PBS washes, tissue slices were
transferred to the VectaStain ABC reagent mixture and left for 1 hr; the slices were then stained
using the DAB method (Vector Laboratories) with 0.0063% H2O2, 0.05% DAB, 0.0075%
NiAmSO4, and 0.005% CaCl2. As a control to assess potential nonspecific staining, some
sections were run through the assay without primary or without secondary antibody, and no
staining occurred. Slices were mounted onto microslides using ShurMount mounting media
(Durham, NC). Flat-field corrected digital pictures (8-bit gray scale) were taken on a SPOT
camera (model 1.1.0, SPOT, Melville, NY) connected to an Olympus BX60 scope (10–20×
objectives) with accompanying software (SPOT version 3.5.8). Image J software was used to
process background (noncellular regions or corpus callosum) and signal (cell body or
processes) intensities that were standardized with densitometric standards (Kodak T14 Control
Scale, Kodak, Rochester, NY). As above, anatomically matched pictures of the left and right
sides of the brain were used to produce an average density for each brain region in each animal.
Data were presented as background-corrected standardized image densities for each brain
region.
Data Analyses
For each brain region examined, differences between C57BL/6J and DBA/2J mice were
analyzed using one-way analysis of variance (ANOVA). In all cases, p < 0.05 (two-tailed) was
used to indicate statistical significance.
RESULTS
NPY Immunoreactivity
In general, differences in NPY IR between the strains were observed within the extended
amygdala but not within hypothalamic nuclei. Representative photomicrographs and data of
NPY IR in the nucleus accumbens (NAc) are depicted in Fig. 1A and 1B. Relative to the low
alcohol drinking DBA/2J mice, the high alcohol drinking C57BL/6J mice showed lower NPY
IR in the shell of the NAc (Fig. 1C), an observation confirmed by statistically significant results
of analysis of variance [F(1,16) = 7.04; p = 0.02]. Importantly, strain differences in NPY IR
were specific to the NAc shell, because C57BL/6J and DBA/2J mice showed similar NPY IR
in the NAc core (Fig. 1D) [F(1,16) = 7.04; p = 0.33]. Representative photomicrographs and
data of NPY IR in the amygdala are depicted in Fig. 2A and 2B. Analyses revealed that the
C57BL/6J mice showed significantly lower NPY IR in the central nucleus of the amygdala
[F(1,16) = 4.36; p = 0.05] and the basolateral amygdala [F(1,16) = 6.23; p = 0.02] (Fig. 2C
and 2D). Photomicrographs of NPY IR in the paraventricular nuclei and arcuate nuclei of the
hypothalamus are shown in Fig. 3A-3D. NPY IR did not significantly differ between the strains
in the arcuate nucleus [F(1,18) = 0.90; p = 0.36] or the paraventricular nucleus [F(1,19) = 0.20;
p = 0.66] (Fig. 4).
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Representative photomicrographs of CRF IR in the NAc and amygdala of C57BL/6J and DBA/
2J mice are shown in Fig. 5A-5D, and a graphical representation of all quantified CRF IR is
presented in Fig. 6. There were no observed statistical differences between strains in CRF IR
within the NAc shell [F(1,22) = 3.63; p = 0.07] or core [F(1,22) = 2.85; p = 0.12], the basolateral
amygdala [F(1,23) = 1.27; p = 0.27] or central nucleus of the amygdala [F(1,20) = 3.96; p =
0.06], or the arcuate nucleus of the hypothalamus [F(1,20) = 0.31; p = 0.58]. Due to lack of
tissue, quantification of CRF IR in the paraventricular nucleus of the hypothalamus was not
possible. As an alternative region, we quantified CRF IR in the suprachiasmatic nucleus of the
hypothalamus because the suprachiasmatic nucleus is a major source of CRF that innervates
the paraventricular nucleus (Vrang et al., 1995). Consistent with other regions, there were no
strain differences in CRF IR in the supra-chiasmatic nucleus [F(1,18) = 0.46; p = 0.51].
DISCUSSION
We show that relative to the low ethanol drinking DBA/2J mice, the high ethanol consuming
C57BL/6J mice have significantly lower baseline levels of NPY in several regions of the
extended amygdala, namely, the shell of the NAc (Fig. 1C) and the central nuclei (Fig. 2C)
and baso-lateral amygdala (Fig. 2D). These findings are consistent with and extend a recent
report that also found low levels of NPY in the shell of the NAc of C57BL/6J mice relative to
DBA/2J mice (Misra and Pandey, 2003). On the other hand, there are no strain differences in
NPY levels in the core of the NAc or various nuclei examined within the hypothalamus.
Although the present results do not provide a causal link between NPY and ethanol
consumption, these findings offer an initial comparison of basal NPY levels between inbred
strains of mice that show extreme differences in ethanol preference (Belknap et al., 1993;Le
et al., 1994;Meliska et al., 1995;Mittleman et al., 2003;Risinger et al., 1998). However, utilizing
genetically altered mice, it has been shown that mice lacking NPY consume significantly higher
amounts of ethanol than do wild-type strains, while mice that overexpress the NPY gene exhibit
a reduced preference for ethanol (Thiele et al., 1998). Therefore, taken together with this
previous research, these data suggest the possibility that low NPY levels, in part, may contribute
to the high ethanol consumption characteristic of C57BL/6J mice. Despite strain differences
in NPY levels and contrary to expectations, the C57BL/6J and DBA/2J mice do not differ in
baseline CRF levels in any of the regions examined.
It must be cautioned that differential expression of NPY between C57BL/6J and DBA/2J mice
may modulate any of a number of phenotypic parameters that differ between these strains, and
in fact, differences in ethanol consumption between strains could be completely independent
of NPY signaling. However, the observation that low basal NPY levels are associated with
high ethanol intake in inbred mice is consistent with several other reports in the literature. The
selectively bred P and HAD rat lines show low NPY levels in the amygdala (Ehlers et al.,
1998; Hwang et al., 1999), and voluntary ethanol consumption is inversely related to NPY
signaling in knockout and trans-genic mice (Thiele et al., 1998, 2002, 2000b, 2004a). In
addition, amygdalar infusion of a PKA inhibitor causes local reductions of NPY levels that are
associated with increased ethanol intake in Sprague Dawley rats, and furthermore, elevated
levels of ethanol drinking are rescued by amygdalar coadministration of NPY (Pandey et al.,
2003b). Thus, the present results are consistent with previous research and further suggest that
low NPY levels, specifically within the extended amygdala, predispose high ethanol
consumption. Hypothalamic infusion of NPY increases ethanol intake by Long-Evans rats
(Kelley et al., 2001). However, because the C57BL/6J and DBA/2J mice do not differ in
hypothalamic NPY levels, it is unlikely that hypothalamic NPY levels modulate ethanol intake
by these inbred strains.
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It is of interest to consider the possible mechanisms by which NPY signaling modulates ethanol
consumption. Because of their opposing actions, it has been suggested that CRF and NPY exert
a reciprocal regulation of drug self-administration through allostatic interactions within the
extended amygdala (Koob, 2003; Koob and Le Moal, 2001). Theoretically, repeated abstinence
and relapse weaken the NPY system and augment CRF signaling, ultimately creating an
imbalance that results in reduced sensitivity to drug reward and a negative affective state and
that increases the likelihood of relapse and uncontrolled ethanol drinking. We suggest that our
observations are in fact consistent with the allostasis model of uncontrolled ethanol drinking
(Koob, 2003; Koob and Le Moal, 2001). Relative to DBA/2J mice, C57BL/6J mice have low
baseline NPY levels but similar CRF expression. Viewed this way, naive C57BL/6J mice
possess an inherent imbalance between NPY and CRF that theoretically resembles a dependent
animal. This inherent imbalance, in turn, could motivate the high ethanol drinking that is
characteristic of C57BL/6 mice with little or no prior ethanol experience.
It has been suggested that factors that may contribute to the initiation of ethanol consumption
and/or continued use of this drug include high basal levels of anxiety and increased anxiety
caused by ethanol withdrawal (Bibb and Chambless, 1986; Cappell and Herman, 1972;
Cornelius et al., 2003; Koob, 2003; Schuckit and Hesselbrock, 1994). NPY possesses
anxiolytic properties when infused into the amygdala (Heilig et al., 1993, 1989). Thus,
organisms with innately low levels of NPY, or with low levels of NPY caused by withdrawal,
may drink increased amounts of ethanol in an attempt to reduce anxiety (i.e., increased ethanol
drinking represents self-medication) (Pandey, 2003; Pandey et al., 2003a; Thiele et al.,
2004b). Consistent with this view, P rats, which have low amygdalar NPY levels (Ehlers et
al., 1998; Hwang et al., 1999), show high basal levels of anxiety (Stewart et al., 1993) that may
predispose them to drink large quantities of ethanol. Central infusion of NPY may rescue the
high ethanol drinking in P rats by reducing their high levels of anxiety (Badia-Elder et al.,
2000; Stewart et al., 1993). However, C57BL/6J mice show low basal levels of anxiety when
compared with DBA/2J mice (Griebel et al., 2000; Lamberty, 1998; Misra and Pandey,
2003; Ohl et al., 2001), thus making altered anxiety an unlikely explanation of increased ethanol
drinking by the C57BL/6J strain.
It has also been suggested that NPY may influence ethanol consumption by modulating the
sedative effects of this drug. There is increasing evidence from both human and animal research
indicating that resistance to the intoxicating effects of ethanol is often associated with high
levels of ethanol drinking (Schuckit, 1986, 1988, 1994). Low NPY signaling is associated with
increased ethanol consumption and resistance to the sedative effects of ethanol, while NPY
overexpression promotes increased sensitivity to ethanol-induced sedation and inhibits ethanol
drinking (Thiele et al., 1998, 2002). Interestingly, there is evidence that C57BL/6J mice are
less sensitive to ethanol-induced sedation than DBA/2J mice (Camjanovich and MacInnes,
1973; Tabakoff and Ritzmann, 1979), which could be the result of low NPY signaling.
However, differences in sensitivity to the sedative effects of ethanol between C57BL/6J and
DBA/2J mice have not always been observed (Alkana et al., 1988; Browman et al., 2000).
Finally, it has been suggested that central NPY signaling modulates the rewarding properties
associated with ethanol (Thiele et al., 2004b). The NAc is a brain region with one of the highest
levels of NPY IR (Hendry, 1993). Furthermore, the NAc is thought to be a key brain region
for the modulation of ethanol reward (Koob, 2003). NPY infused directly into the NAc supports
conditioned place preference in rats; thus, NPY signaling in the NAc is apparently rewarding
(Brown et al., 2000; Josselyn and Beninger, 1993). In addition, pretreatment with a dopamine
receptor antagonist prevents NPY from producing a conditioned place preference, a finding
that suggests that NPY-mediated reward involves an interaction with the dopamine system
(Josselyn and Beninger, 1993). Thus, low NPY function in the NAc may, in part, drive the
high ethanol drinking in C57BL/6 mice (Misra and Pandey, 2003; Thiele et al., 2004b).
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In summary, we provide an initial comparison of basal NPY and CRF levels between C57BL/
6J and DBA/2J mice, strains that differ dramatically in their level of voluntary ethanol
consumption. Relative to DBA/2J mice, the C57BL/6J strain showed significantly lower NPY
levels within the amygdala and the shell region of the NAc. However, there were no
corresponding differences in CRF levels between the strains. These findings suggest that low
NPY levels, and possibly an imbalance between NPY and CRF, contribute to the high ethanol
consumption characteristic of C57BL/6J mice. However, to firmly establish the possible role
of endogenous NPY signaling in ethanol intake by inbred mice, future research will involve a
systematic assessment of mechanisms affecting NPY function, at baseline and in response to
an ethanol challenge, over a range of inbred strains that differ in ethanol intake. It will also be
necessary to determine and control for strain differences in synthesis, storage, and release of
NPY, as well as possible stain differences in NPY receptor subtype populations. Future
research should also include female animals to address the possibility that these differences
may be attributable to gender effects.
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NPY immunofluorescence in the NAc. Representative photomicrographs are coronal brain
slices (at approximately 1.0 mm anterior to bregma) taken from C57BL/6J (A) and DBA/2J
(B) mice. Quantification of immunofluorescence in the shell (C) and core (D) regions of the
NAc were performed using Image J software, and values are represented as mean area ± SEM.
*p < 0.05.
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NPY immunofluorescence in the amygdala. Representative photomicrographs are coronal
brain slices (at approximately 1.5 mm posterior to bregma) taken from C57BL/6J (A) and DBA/
2J (B) mice. Quantification of immunofluorescence in the central nucleus (CEA) of the
amygdala (C) and the basolateral (BLA) amygdala (D) were performed using Image J software,
and values are represented as mean area ± SEM. *p < 0.05.
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NPY immunofluorescence in the hypothalamus. Representative photomicrographs are coronal
brain slices taken from C57BL/6J (A and C) and DBA/2J (B and D) mice in the paraventricular
nucleus of the hypothalamus (A and B) and the arcuate nucleus of the hypothalamus (C and
D).
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Quantification of immunofluorescence in the paraventricular nucleus (A) and arcuate nucleus
(B) of the hypothalamus was performed using Image J software, and values are represented as
mean area ± SEM. *p < 0.05.
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CRF IR in the NAc (A and B) and the amygdala (C and D). Representative photomicrographs
are coronal brain slices taken from C57BL/6J (A and C) and DBA/2J (B and D) mice.
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Mean area of CRF IR quantification was performed using Image J software. Values are
expressed as mean area ± SEM.
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